Why did ECX.F stock drop 21.10% today?

The drop reflects very low liquidity, a gap lower from **€1.09** to **€0.93** at the open, and thin volume of **314** shares. Market reassessment of Epigenomics’ limited operations and negative EPS **-3.15** amplified selling pressure.

What is Meyka AI's forecast for ECX.F?

Meyka AI's forecast model projects **€0.75** monthly and **€1.52** quarterly. The monthly projection implies a **-12.79%** move from **€0.86**, while the quarterly implies **+76.74%**. Forecasts are model-based projections and not guarantees.

What are the main financial risks for Epigenomics AG (ECX.F)?

Major risks include persistent losses (EPS **-3.15**), negative operating cash flow per share **-6.51**, high debt-to-assets **0.96**, and low market cap **€754,176**, all raising dilution and solvency concerns.

Should investors hold or sell ECX.F now?

Meyka AI assigns a Grade B and suggests HOLD based on a 62.85 score. Given low liquidity and operational uncertainty, investors should limit position size and wait for clearer corporate updates or stronger volume before adding exposure.

DE Stocks

ECX.F Epigenomics (XETRA) down 21.10% to €0.86: liquidity and valuation risk

ByHuzaifa Zahoor February 18, 2026

The ECX.F stock plunged 21.10% to €0.86 on XETRA as volume stayed thin at 314 shares on 17 Feb 2026. This move followed a gap lower from an open of €0.93 and a prior close of €1.09, highlighting volatile trading in a tiny market-cap position of €754,176. Investors should note Epigenomics (ECX.F) reports persistent losses (EPS -3.15) and a negative PE of -0.27, which link valuation to company operational inactivity. Meyka AI’s real-time model and the company website provide context for the drop and near-term liquidity risks source.